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Abstract 
Pharmacovigilance is defined as “the pharmacological science relating to the detection, assessment, understanding and prevention of 
adverse effects, principally long term and short term adverse effects of medicines.” It is an important and integral part of clinical 
research. India is the world’s second most populated country with over one billion potential drug consumers. Although, India is 
participating in the Uppsala monitoring center program, its contribution to that database is relatively small. This problem is 
essentially due to the absence of a robust ADR monitoring system and also the lack of awareness of reporting concepts among Indian 
health care professionals. The specific aims of pharmacovigilance are to advance patient care and safety in relation to the use of 
medicines and all medical and paramedical interventions, contribute to the assessment of benefit, harm, effectiveness, and risk of 
medicines, promising their safe, rational, and more effective  use, promote indulgent, education, and clinical training in 
pharmacovigilance and its effective communication to the public. Pharmacovigilance methods must also be capable to designate 
which patients are at risk of developing an adverse drug reaction. A suitably working pharmacovigilance system is important if 
medicines are to be used prudently. It will be advantageous for healthcare professionals, regulatory authorities, pharmaceutical 
companies and consumers to monitor medicines for risk.  
 
 
Introduction 
The world health organization (WHO) initiated a program for 
reporting all adverse reactions possessed by drugs. Further 
awareness about adverse drug reactions has resulted in the 
emergence of the practice and science of pharmacovigilance.1 
The word pharmacovigilance is derived from the Greek word 
pharmacon meaning ‘drug’ and the Latin word vigilare 
meaning ‘to keep awake or alert, to keep watch.’ 
Pharmacovigilance is defined as “the pharmacological science 
relating to the recognition, assessment, understanding and 
prevention of adverse effects, particularly long term and 
short term adverse effects of medicines.” 2, 3 After discovery 
and pre-clinical phases, a drug typically undergoes trials in 
human volunteers. Clinical trials are highly regulated and 
closely monitored by the investigators and the manufacturing 
company. It is a mandatory regulatory requirement to report 
all the adverse events in a clinical trial setting in a given time 
frame. In the clinical trial setting, “good clinical practice” has 
moved pharmacovigilance from a reactive to a proactive 
approach. A robust, well-defined system for monitoring 
adverse events is in a place for evaluating the safety of the 
drugs. 4 Pharmacovigilance serves various roles such as 
identification, quantification and documentation of drug- 
related problems which are responsible for drug-related 
injuries. 5, 6 
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India is the world’s second most populated country with over 
one billion potential drug consumers. Although, India is 
participating in the Uppsala monitoring center program, its 
contribution to this database is relatively small. This problem 
is essentially due to the absence of a robust adverse drug 
reaction monitoring system and also the lack of awareness of 
reporting concepts among Indian health care professionals. In 
India, it is very important to focus the attention of the 
medical community on the importance of adverse drug 
reporting to ensure maximum benefits for public health and 
safety. For regulatory reporting purposes, if an event is 
instinctively reported, even if the relationship is mysterious 
or unstated, it meets the definition of an adverse drug 
reaction.  
 
An adverse event is any untoward medical occurrence in a 
patient who is administered a medicinal product and which 
doesn’t necessarily have a causal relationship with this 
treatment. Adverse drug reactions are noxious and 
unintended responses to a medicinal product. A reaction, in 
contrast to an event, is characterized by the fact that a causal 
relationship between the drug and the occurrence are 
supposed. 7, 8 
A serious adverse event (SAE) is any untoward medical 
manifestation, that at any dose: 
• Results in death 
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• Is life-threatening (well-defined as an event in which 
the subject was at risk of death at the time of the 
event) 
• Requires in-patient hospitalization or causes 
prolongation of existing hospitalization 
• Results in persistent or significant 
disability/incapacity 
• Is a congenital anomaly/birth defect 
• Is an important medical event (defined as a medical 
event(s) that may not be immediately life-
threatening or result in death or hospitalization but, 
based upon suitable medical & scientific judgment, 
may require intervention to prevent one of the 
serious outcomes as listed above). 9, 10 
This review article provides a brief overview of the current 
situation and the future prospects of pharmacovigilance in 
India.  
The Pharmacovigilance exertion in India is organized by The 
Indian Pharmacopoeia Commission and conducted by the 
Central Drugs Standard Control Organization (CDSCO). The 
main responsibility of the IPC is to maintain and develop the 
pharmacovigilance database consisting of all suspected 
serious adverse reactions to medicines observed. Indian 
Pharmacopoeia Commission (IPC) is functioning as a National 
Coordination Centre (NCC) for Pharmacovigilance Programme 
of India (PvPI). National Coordination Centre is operating 
under the observation of steering committee which 
recommends procedures and guidelines for regulatory 
interventions. The main duty of National Coordination Centre 
is to monitor all the adverse reactions of medicines being 
observed in the Indian population and to develop and 
maintain its own pharmacovigilance database. 
Pharmacovigilance Programme of India (PvPI) 
The Central Drugs Standard Control Organization (CDSCO), 
Directorate General of Health Services under the aegis of 
Ministry of Health & Family Welfare, Government of India in 
association with Indian Pharmacopeia commission, Ghaziabad 
is initiating a nation-wide Pharmacovigilance Programme for 
protecting the health of the patients by promising drug 
safety. The Programme shall be coordinated by the Indian 
Pharmacopeia commission, Ghaziabad as a National 
Coordinating Centre (NCC). The center will operate under the 
supervision of a Steering Committee.  
The Pharmacovigilance Programme of India (PvPI) was started 
by the Government of India on 14th July 2010 with the All 
India Institute of Medical Sciences (AIIMS), New Delhi as the 
National Coordination Centre for monitoring Adverse Drug 
Reactions (ADRs) in the country for safe-guarding Public 
Health. In the year 2010, 22 ADR monitoring centres including 
AIIMS, New Delhi was set up under this Programme. To 
safeguard implementation of this programme in a more 
effective way, the National Coordination Centre was shifted 
from the All India Institute of Medical Sciences (AIIMS), New 
Delhi to the Indian Pharmacopoeia Commission, Ghaziabad, 
Uttar Pradesh on 15th April 2011. 
Before registration and marketing of medicine in the country, 
its safety and efficacy experience is based chiefly on the use 
of the medicine in clinical trials. These trials primarily detect 
common adverse reactions. Some important reactions, such 
as those, which take a long time to develop, or those, which 
occur rarely, may not be detected in clinical trials. In addition, 
the controlled conditions under which medicines are used in 
clinical trials do not necessarily reflect the way they will be 
used in practice. For a medicine to be considered safe, its 
predictable benefits should be greater than any associated 
risks of harmful reactions. So, in order to gain a complete 
safety profile of medicine, a continuous post-marketing 
monitoring system i.e. pharmacovigilance is essential. In 
order to screen the safety of medicine, information from 
many sources is used for pharmacovigilance. These include 
spontaneous (ADRs) reporting mechanism; medical literature 
published worldwide, action taken by regulatory authorities 
in other countries, etc. Meanwhile there exist considerable 
social and economic consequences of adverse drug reactions 
and the positive benefit/cost ratio of employing appropriate 
risk management (there is a need to engage healthcare 
professionals and the public at large, in a well-structured 
programme to build synergies for monitoring adverse drug 
reactions in the country). The purpose of the PvPI is to collate 
data, process and analyze it and use the inferences to 
recommend regulatory interventions, besides communicating 
risks to healthcare professionals and the public. 
Mission: Safeguard the health of the Indian population by 
ensuring that the benefits of use of medicine outweigh the 
risks associated with its use. 
Vision: To improve patient safety and welfare in Indian 
population by monitoring the drug safety and thereby 
reducing the risk associated with use of medicines. 
Objectives 
• To create a nation-wide system for patient safety 
reporting 
• To identify and analyze the new signal (ADR) from 
the reported cases 
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• To analyses the benefit - risk ratio of marketed 
medications 
• To generate the evidence based information on 
safety of medicines 
• To support regulatory agencies in the decision-
making process on use of medications 
• To communicate the safety information on use of 
medicines to various stakeholders to minimize the 
risk 
• To emerge as a national center of excellence for 
pharmacovigilance activities 
• To collaborate with other national centers for the 
exchange of information and data management 
• To provide training and consultancy support to other 
national pharmacovigilance centers located across 
globe11 
Implementation of PvPI 
IPC assumed the need for establishing local hospital based 
centers across the nation for the better patient safety. It was 
significant to monitor both the known and previously 
unknown side effects of medicines in order to determine any 
new information available in relation to their safety profile. In 
an enormous country like India with a population of over 1.2 
billion and with vast ethnic variability, different disease 
prevalence patterns, practice of different systems of 
medicines, different socioeconomic status, it was imperative 
to have a standardized and robust pharmacovigilance and 
drug safety monitoring programme for the nation. 
Short term goals 
• To develop and implement pharmacovigilance 
system in India 
• To enroll, initially, all MCI approved medical colleges 
in the program covering north, south, east and west 
of India 
• To encourage healthcare professionals in reporting 
of adverse reaction to drugs, vaccines, medical 
devices and biological products 
• Collection of case reports and data 
Long term goals 
 
• To expand the pharmacovigilance programme to all 
hospitals (govt. & private) and centers of public 
health programs located across India 
• To develop and implement electronic reporting 
system (e-reporting) 
• To develop reporting culture amongst healthcare 
professionals 
• To make ADR reporting mandatory for healthcare 
professionals 
Effective communication channels are the key to a successful 
running of PvPI. The Indian pharmacopoeia commission was 
summarized in Figure 1. Program communications is 
described in Figure 2 and ADR monitoring centers are 
displayed in Figure 3. The functions of the ADR monitoring 
center are shown in Figure 4 with regional resources for 
training in India summarized in figure 5. The process of 
collection, analysis and evaluation of ADRs are described in 
Figure 6. 
Causes of failure of implementation of pharmacovigilance in 
India 
Many new drugs are being introduced in the country, so 
there is a need to improve the pharmacovigilance system in 
order to protect the Indian population from potential harm 
that may be caused by some of the new drugs. However, 
there are numerous issues and problems that have prevented 
building a robust pharmacovigilance system, which are 
described below: 
1. Pharmacovigilance systems are not well-funded and 
systematized for a vast country like India to serve 
patients and the public. 
2. The data obtained to date in the zonal centers from 
various peripheral centers is often poor and not 
well-analyzed. There is inadequate research on ADRs 
in India, so the exact incidence of specific ADRs is 
unknown. 
3. Involvement of healthcare professionals (both in 
rural areas and urban cities and hospitals) and 
knowledge and motivation for pharmacovigilance is 
negligible. There little encouragement from the 
department of health to provide more training and 
create more awareness amongst them for better 
reporting. 
4. In India, there are several consumers' groups who 
encourage patients to report any adverse reactions 
encountered by them, although there is no 
information for patients to report ADRs directly to 
the regulatory authority. 
Pharmacovigilance Methods 
Passive surveillance: 
• encompasses all spontaneous AEFI reporting 
• from immunisation service providers / hospitals / 
patients 
http://z.umn.edu/INNOVATIONS                     2015, Vol. 6, No. 1, Article 189                           INNOVATIONS in pharmacy   3 
 
Commentary POLICY 
 
• up to next levels: state/territory then national (TGA) 
and then global 
Active surveillance: 
• primarily used for characterization of the AEFI profile, 
rates and risk factors 
• logistical and resource constraints limit wide 
application 
• only for selected AEFI at selected institutions (sentinel) 
sites 
• can also be carried out in the community setting (e.g. 
cohort event monitoring) 
Ad hoc studies: 
• epidemiological studies (e.g. cohort study, case-control 
study, case series studies) 
• focus on selected vaccine safety concerns (e.g. testing 
causality hypotheses) 
• retrospective or prospective 
I. Passive surveillance 
a) Spontaneous reports 
A spontaneous report is a voluntary communication by 
healthcare professionals or consumers to a company, 
regulatory authority or other organization that defines one or 
more adverse drug reactions (ADRs) in a patient who was 
given one or more medicinal products and that does not 
originate from a study or any structured data collection 
scheme. 12 It plays a key role in the identification of safety 
signals once a medicine is marketed. In various occurrences, 
spontaneous reports can vigilant a company to rare adverse 
events that were not noticed in earlier clinical trials or other 
pre-marketing studies. It can also deliver important 
information on at-risk groups, risk factors and clinical features 
of known serious ADRs. 13-16  
Newly, systematic methods for the recognition of safety 
signals from spontaneous reports have begun to be used. 
Several of these methods are static in development and their 
utility for identifying safety signals is being assessed. These 
methods include the calculation of the proportional reporting 
ratio, as well as the use of Bayesian and other techniques for 
signal detection. 17-19 Data mining techniques have also been 
used to examine medicine-medicine interactions 20, but these 
techniques should always be used in conjunction with, and 
not in place of, analyses of single case-reports. Data mining 
techniques facilitate the evaluation of spontaneous reports 
by using statistical methods to detect potential signals that 
merit further evaluation. However, this tool does not quantify 
the magnitude of risk, and caution should be exercised when 
comparing medicines. Further, when using data mining 
techniques, consideration should be given to the threshold 
established for detecting signals, since this will have 
implications for the sensitivity and specificity of the method 
(a high threshold is associated with high specificity and low 
sensitivity). Confounding factors that influence reporting of 
spontaneous adverse events are not removed from data 
mining. The results of data mining should thus be interpreted 
with the knowledge of the weaknesses of the spontaneous 
reporting system and, more specifically, the large differences 
in the ADR reporting rate for different medicines and the 
many potential biases inherent in spontaneous reporting. All 
signals should be evaluated while recognizing the possibility 
of false-positives. In addition, the absence of a signal does not 
mean that a problem does not exist. 
b) Case series 
A series of case-reports can deliver signs of an association 
between a medicine and an adverse event, but they are 
normally more valuable for producing theories than for 
confirming a relationship between medicine exposure and 
outcome. 21, 22 
c) Stimulated reporting 
A number of methods have been used to reassure and 
simplify reporting by health professionals in definite 
circumstances for new products or for partial time periods. 23 
Such systems comprise on-line reporting of adverse events 
and methodical motivation of reporting of adverse events 
based on a pre-designed method. While these methods have 
been shown to advance reporting, they are not invulnerable 
to the confines of passive surveillance, particularly 
discriminating reporting and imperfect information. This 
should be considered as a procedure of spontaneous event 
reporting, and thus data acquired from stimulated reporting 
cannot be used to make precise incidence rates, but reporting 
rates can be projected. 
II) Active surveillance 
Active surveillance, in contrast to passive surveillance, 
pursues to determine the particular number of adverse 
events through a constant pre-organized process. 24 In 
common, it is more achievable to acquire wide-ranging data 
on discrete adverse event reports through an active 
surveillance system than through a passive reporting system.  
a) Sentinel sites 
Active surveillance can be attained by revising medical 
records or questioning patients and/or physicians in a section 
of sentinel sites to guarantee that comprehensive and precise 
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data on reported adverse events are collected from these 
sites. The selected sites can deliver information, such as data 
from specific patient subgroups, which would not be 
accessible in a passive spontaneous reporting system. 25 The 
major weaknesses of sentinel sites comprise difficulties with 
selection bias, small numbers of patients and augmented 
costs. Active surveillance with sentinel sites is most effective 
for those medicines used primarily in institutional settings 
such as hospitals, nursing homes and haemodialysis centers. 
Institutional settings may use certain medicinal products 
more commonly and can deliver an arrangement for 
enthusiastic reporting. Intensive monitoring of sentinel sites 
can also be supportive in recognizing risks among patients 
taking orphan medicines.  
b) Medicine event monitoring 
This is a process of active Pharmacovigilance surveillance. 
Studies using this process are cohort-based and prospective 
and observational. For medication event monitoring, patients 
can be acknowledged from electronic or automated health 
insurance claims. A single prescription or a series might be 
composed over the period of monitoring. A follow-up 
questionnaire can then be sent to each prescribing physician 
or patient at pre-specified intervals to acquire outcome data. 
Requests for data on patient demographics, indication for 
treatment, duration of therapy, dosage, clinical events, 
reasons for termination and applicable past history can be 
involved in the questionnaires. 26-30 The restrictions of 
medicine event monitoring can comprise the poor physician 
and patient reply rates. 31, 32 
c) Registries 
A registry is a list of patients presenting with the identical 
representative(s). This representative can be a disease 
(disease registry) or a specific exposure (medicine registry). 
Both types of registrations, which vary only by the type of 
patient data of interest, can gather a cordless of information 
using standardized questionnaires in a prospective fashion. 
Disease registries, such as registries for blood dyscrasias, 
severe cutaneous reactions, or congenital malformations can 
help to gather data on medicine exposure and other factors 
related to a clinical condition. A disease registry might also be 
used as a veil for a case control study associating the 
medicine exposure of cases recognized from the registry with 
controls selected either from patients with another condition 
within the registry, or from patients outside the registry. 
Exposure (medicine) registries address populations exposed 
to the medicines of interest to govern if a medicine has a 
distinct influence on this group of patients. Some exposure 
(medicine) registries address drug exposures in specific 
populations, such as pregnant women. Patients can be 
followed over time and included in a cohort study to collect 
data on adverse events using standardized questionnaires. 
Single cohort studies can quantity incidence, but, without a 
comparison group, cannot deliver proof of association. This 
type of registry can be very valuable when examining the 
safety of an orphan medicine indicated for a specific 
condition. Customary epidemiological methods are a key 
constituent in the evaluation of adverse events. There are 
numerous of observational study designs that are valuable in 
validating signals from spontaneous reports, case series or 
medicine event monitoring. The most imperative of these 
designs is cross-sectional studies, case-control studies and 
cohort studies. 33, 34 
d) Cross-sectional study (survey)  
Data collected on inhabitants of patients during a specified 
interval of time, regardless of exposure or disease status 
constitute a cross-sectional study. These types of studies are 
principally used to collect data for surveys or for ecological 
analyses. The major disadvantage of cross-sectional studies is 
that the temporal relationship between exposure and 
outcome cannot be straight addressed. These studies are 
paramount used to scrutinize the prevalence of a disease at 
one time point or to inspect trends over time, when data for 
serial time points can be captured. These studies can also be 
used to observe the crude relationship between exposure 
and outcome in ecological analyses. Cross-sectional studies 
are utmost valuable when exposures do not change over 
time. 
e) Case-control study 
In a case-control study, cases of disease (or events) are 
recognized. Controls, or patients in whom the disease or 
event of interest has not happened, are then carefully chosen 
from the source population that gave rise to the cases. The 
controls should be selected in such a way that the prevalence 
of exposure among the controls exemplifies the prevalence of 
exposure in the source population. The exposure status of the 
two groups is then paralleled using the odds ratio, which is an 
estimate of the relative risk of disease in the two groups. 
Patients can be acknowledged from an existing database or 
using data collected unambiguously for the purpose of the 
study. If safety data is sought for special populations, the 
cases and controls can be stratified according to the 
population of interest. For rare adverse events, prevailing 
large population-based databases are a useful and efficient 
means of providing the necessary data on medicine exposure 
and medical outcome relatively quickly. Case-control studies 
are predominantly useful when the goal is to examine 
whether there is a relationship between a medicine (or 
medicines) and one specific rare adverse event, as well as to 
identify risk factors for adverse events. Risk factors can 
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include conditions, such as renal and hepatic dysfunction, 
which might modify the relationship between the medicine 
exposure and the adverse event. Under particular conditions, 
a case-control study can deliver the complete incidence rate 
of the event.  
f) Cohort study 
In a cohort study, a population at risk for the disease (or 
event) is monitored over time to record the occurrence of the 
disease (or event). Information on exposure status is 
accessible during the follow-up period for each patient. A 
patient might be exposed to a medicine at one time during 
follow-up, but not exposed at another time. Meanwhile the 
population exposure during follow-up is acknowledged, 
incidence rates can be calculated. In many cohort studies 
concerning medicine exposure, appraisal cohorts of interest 
are selected on the basis of medicine use and monitored over 
time. Cohort studies are useful when there is a requisite to 
know the incidence rates of adverse events in addition to the 
relative risks. Multiple adverse events can also be scrutinized 
using the similar data source in a cohort study. Conversely, it 
can be problematic to recruit adequate numbers of patients 
who are exposed to the medicine of interest or to study very 
rare outcomes. Similar to case-control studies, patients in 
cohort studies can be recognized from large automated 
databases or from data collected precisely for the study at 
hand. In addition, cohort studies can be used to scrutinize 
safety issues in special populations through oversampling of 
these patients or by stratifying the cohort if adequate 
numbers of patients are included. There are numerous 
automated databases obtainable for 
pharmacoepidemiological studies.35, 36, 37 They consist of 
databases that contain automated medical records or 
automated accounting/billing systems. Databases that are 
fashioned from accounting/billing systems might be 
connected to pharmacy claims and medical claims databases. 
These datasets may contain millions of patients. 
Subsequently, they are fashioned for administrative or billing 
purposes; they might not have all the detailed and precise 
information needed for some research, such as authenticated 
diagnostic information or laboratory data. Even though 
medical records can be used to establish and authenticate 
test results and medical diagnoses, one should know about 
the privacy and privacy regulations that apply to patient 
medical records. 
g) Targeted clinical investigations 
When significant risks are identified from pre-approval clinical 
trials, further clinical studies might be called in to evaluate 
the mechanism of action for the adverse reaction. In some 
instances, pharmacodynamics and pharmacokinetic studies 
might be conducted to define whether a particular dosing 
instruction can put patients at an increased risk of adverse 
events. Moreover, based on the pharmacological properties 
and the predictable use of the medicine in general practice, 
conducting specific studies to scrutinize potential medicine-
medicine interactions and food-medicine interactions might 
be entitled to. These studies can comprise population 
pharmacokinetics studies and medicine concentration 
monitoring in patients and normal volunteers. One drawback 
of this method is that the outcome measure might be too 
shortened and this might have an influence on the quality 
and eventual usefulness of the results of the trial. Large, 
simplified trials are similarly resource-intensive.  
Descriptive studies 
Descriptive studies are a vital component of 
Pharmacovigilance, even though not for the recognition or 
authentication of adverse events related to medicine 
exposures. These studies are principally used to acquire the 
circumstantial rate of outcome events and/or to inaugurate 
the prevalence of the use of medicines in specified 
populations. 
a) Natural history of disease 
The discipline of epidemiology initially concentrated on the 
natural history of disease, including the features of diseased 
patients and the dissemination of disease, in particular 
populations, as well as appraising the incidence and 
prevalence of possible outcomes of interest. These outcomes 
of interest currently comprise a narrative of disease 
treatment outlines and adverse events. Studies that 
scrutinize precise facts of adverse events, such as the 
contextual incidence rate of, or risk factors for, the adverse 
event of interest, can assist in placing spontaneous reports 
into viewpoint. 38  
b) Medicine utilization study 
Medicine utilization studies (DUS) define how a medicine is 
marketed, prescribed and used in a population, and how 
these factors affect outcomes (including clinical, social and 
economic outcomes). 39These studies deliver data on definite 
populations, such as the elderly, children, or patients with 
hepatic or renal dysfunction, habitually stratified by age, sex, 
concomitant medication and other characteristics. It can be 
used to define if a product is being used in these populations. 
It has been used to define the effect of regulatory actions and 
media courtesy on the use of medicines, as well as to improve 
evaluations of the economic burden of the cost of medicines. 
It can also be used to scrutinize the relationship between 
optional and definite clinical practice. These studies can help 
to govern whether a medicine has the probable for abuse by 
inspecting whether patients are taking mounting doses or 
whether there is an indication of incorrect duplication 
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prescribing. The main limitations of these studies can 
comprise an absence of clinical outcome data or information 
on the indication for use of a product.  
Future aspects of pharmacovigilance in India 
A suitably working pharmacovigilance system is vital if 
medicines are to be used safely. It will advantage all parties 
including healthcare professionals, regulatory authorities, 
pharmaceutical companies and the consumers. It aids 
pharmaceutical companies to monitor their medicines for risk 
and to devise and implement effective risk management 
plans to save their drugs in difficult circumstances.  
Having considered the problems and challenges facing the 
development of a robust pharmacovigilance system for India, 
the following proposals 40 might be follows: 
1. Building and maintaining a robust pharmacovigilance 
system. 
2. Making pharmacovigilance reporting mandatory and 
introducing pharmacovigilance inspections. 
3. High-level discussions with various stakeholders. 
4. Strengthen the drug control general of India office 
with trained scientific and medical assessors for 
pharmacovigilance. 
5. Creating a single country-specific adverse event 
reporting form to be used by all. 
6. Creating a clinical trial and post marketing database 
for SAEs / SUSARs and ADRs for signal detection and 
access to all relevant data from various stakeholders. 
7. List all new drugs / indications by maintaining a 
standard database for every pharmaceutical 
company. 
8. Education and training of medical students, 
pharmacists and nurses in the area of 
pharmacovigilance. 
9. Collaborating with pharmacovigilance organizations 
in enhancing drug safety with advancements in 
information technology, there has been the 
emergence of new opportunities for national and 
international collaborations that can enhance 
postmarking surveillance programs and increase 
drug safety. 41, 42 
10. Building a network of pharmacovigilance and 
pharmacopeidemiologists in India. 
Conclusion 
Pharmacovigilance systems are needed to safeguard public 
health. Diminutive prominence has been put into 
engendering information that can assist a healthcare 
professional or a patient in medication decision-making 
processes. The collecting and dissemination of this 
information is a chief goal of Pharmacovigilance. 
Pharmacovigilance methods must be capable to designate 
which patients are at risk from medication use. A suitably 
working Pharmacovigilance system is important if medicines 
are to be used prudently. It will be advantageous for 
healthcare professionals, regulatory authorities, 
pharmaceutical companies and consumers to monitor 
medicines for risk.  
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Figure 1- Indian pharmacopoeia commission 
 
 
 
The main functions are to maintain the quality of medicines and ensure the safety of medicines. 
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Figure 2- Pharmacovigilance programme communications 
 
 
 
 
This figure explains the process of communication from health care professionals 
 to the adverse drug reaction monitoring centers, zonal offices and to the national coordinating center. 
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Figure 3- ADR monitoring centers 
 
 
 
 
 
Adverse drug reaction monitoring centers are established in 24 states and union territories. 
Sixty adverse drug reaction monitoring centers established in phase-I 
Thirty adverse drug reaction monitoring centers established in phase-II 
Adverse drug reaction monitoring centers are divided into north, east, west and south zones. 
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Figure 4- ADR monitoring center functions 
 
 
 
This figure explains the various responsibilities of their respective adverse drug reaction monitoring centers. 
 
 
 
 
 
Figure 5- Regional resource centers for training 
 
 
There are four regional centers for the purpose of training and  
technical support under national coordinating center. 
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Figure 6- Collection, analysis and evaluation of ADRs 
 
 
 
 
 
This figure explains the flow of adverse drug reaction reporting 
 to the adverse drug reaction monitoring centers. 
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